Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

LeMaitre Vascular Inc (LMAT)

Healthcare Medical Instruments & Supplies
101.30 $
-0.9% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at LeMaitre Vascular Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 8 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Aktien.Guide
Breakout & Setup
Dividends

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap
2.3$B
Shares Outstanding
23Mio.
Float
93.1%
Beta
0.5

Performance

Perf. 1M
1.50%
Perf. 3M
-9.70%
Perf. 6M
14.40%
YTD Performance (%)
13.90%
52-Week-High Distance
-20.4%
Perf. 1Y
11.66%
Perf. 3Y
38.50%
Perf. 5Y
55.05%

Valuation

P/E
Forward P/E
34.4
PEG
2.9
P/B
P/S
9.0
EV/EBITDA
22.6
Price/FCF
29.3

Profitability

Gross Margin
71.3%
EBIT Margin
26.7%
Net Margin
24.3%
Return on Equity
16.6%
Return on Assets
7.2%

Balance Sheet & Safety

Equity Ratio
64.6%
Debt/Equity
fortress balance sheet
Altman Z″
11.72
Piotroski
5 out of 9

Growth

Sales Growth Last Quarter
11.20%
EPS Growth Last Quarter
41.70%
Sales Growth (Year)
13.53%
Forward Sales Growth
9.21%
Forward EPS Growth
8.50%

Dividend

Dividend Yield
0.97%
Dividend Per Share (TTM)
0.90$
Payout Ratio
33.2%
Years Without a Cut
14Years
Increase Streak
14Years

Quality & Screener

Stage
1
RS Rating
32
EPS Rating
75
Piotroski
5 out of 9
Fundamental Rating
B (69 out of 100)
fortress balance sheet
Altman Z″
11.72

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 101.30 $
Price Target (average) 118.75 $

The price target sits 17.2% above the current price.

Consensus
Buy

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

4. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
0.81 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 55.7 $M Q4 2025: Q1 · 59.9 $M Q1 2025: Q2 · 64.2 $M Q2 2025: Q3 · 61.0 $M Q3 2025: Q4 · 64.5 $M Q4 2026: Q1 · 66.6 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.49 29.60 56 14.00 20.10 15 13
2025: Q1 0.48 10.50 60 12.00 18.40 9 8
2025: Q2 0.60 15.70 64 15.00 21.50 20 19
2025: Q3 0.71 45.90 61 11.40 28.40 29 27
2025: Q4 0.68 38.90 65 15.70 24.20 23 21
2026: Q1 0.68 41.60 67 11.20 23.60 15 12
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

LeMaitre Vascular, Inc. entwickelt, fertigt und vermarktet Medizinprodukte und Implantate für die Gefäßchirurgie in Amerika, Europa, dem Nahen Osten, Afrika und im asiatisch-pazifischen Raum.

CEO Insider Trades (12 Mo.)selling own stock
Employees646
HeadquartersBurlington, MA
Websitelemaitre.com
IPO Date19. Oct 2006

Management

Management
Name Title Birth Year
George W. LeMaitre Chairman & CEO 1965
David B. Roberts President & Director 1964
Dorian P. LeBlanc CPA Chief Financial Officer 1975
Trent G. Kamke Senior Vice President of Operations 1971
George D. LeMaitre FACS, M.D. Founder and Chairman of Scientific Advisory Board 1934
Laurie A. Churchill J.D. Chief Legal Officer 1971
Kimberly L. Cieslak Vice President of Marketing 1973
Daniel J. Mumford Senior Director of Human Resources 1982
Jonathan W. Ngau Senior Vice President of Information Technology 1974
Maik D. Helmers Senior Vice President of Sales ? Central Europe 1974

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?